GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated February 16, 2026, reports on the Deferred Annual Bonus Plan (DABP) awards granted on February 12, 2026. The filing covers transactions for Persons Discharging Managerial Responsibilities (PDMRs) who served on the Executive Committee during the year ended December 31, 2025. The awards are granted under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan, approved by shareholders in 2017, and adhere to the Remuneration Policy approved in 2025.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data presented relates to specific equity compensation transactions:
- Transaction Date: February 12, 2026
- Instrument Types: Ordinary Shares (GBP) and American Depositary Shares (USD)
- Share Price (Ordinary Shares): £21.50
- Share Price (ADS): $58.49
- Total Volume (Ordinary Shares): 191,469 shares
- Total Volume (ADS): 6,557 shares
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It strictly details the execution of the annual deferred bonus awards for the 2025 performance year. The awards are subject to a three-year deferral period.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It notes that the awards are exclusive of dividend reinvestment that will accrue during the deferral period. The filing confirms that Executive Directors must defer 50% of bonus equivalent to the first 200% of salary, with the remainder deferred in full, while other Executive Committee members defer 25% of bonus equivalent to the first 170% of salary.
Key Facts for Investor Verification
- Executive Compensation Alignment: Verify that the deferred bonus amounts align with the 2025 Remuneration Policy regarding salary multiples and deferral percentages.
- Share Price Consistency: Confirm the transaction price of £21.50 per Ordinary Share and $58.49 per ADS against the market price on February 12, 2026.
- Deferral Terms: Note that all awards are restricted for a three-year period, impacting immediate liquidity for the recipients.
- Participant Scope: The awards cover 10 senior executives, including the CEO, CFO, and heads of major divisions such as ViiV Healthcare and Global Supply Chain.